S&P 500 Consumer Staples Sector SEC Filings — March 19, 2026

19-03-2026

The Gabelli Global Utility & Income Trust has filed a definitive proxy statement for its Annual Meeting of Shareholders on May 11, 2026, at 10:00 a.m. ET, to elect two Trustees: Salvatore J. Zizza by common and preferred shareholders voting together as a single class, and Leslie F. Foley by preferred shareholders as a separate class. The record date is March 12, 2026, with 5,990,356 Common Shares, 10,977 Series A Preferred Shares, and 484,590 Series B Preferred Shares outstanding; no dividend arrearages exist on Preferred Shares. GAMCO Investors, Inc. and affiliates beneficially own 9.5% of Common Shares.

• ·Quorum requires holders of one-third of outstanding shares entitled to vote; separate one-third quorum for Preferred Shares Trustee election.
• ·Board divided into three classes with staggered three-year terms; all nine Trustees are independent (non-interested persons).
• ·No dividend arrearages on Preferred Shares; Preferred holders entitled to elect majority of Trustees if arrears persist for two years.
• ·Proxy materials mailing begins on or about April 1, 2026; fiscal year ended December 31, 2025.

19-03-2026

The Gabelli Convertible and Income Securities Fund Inc. (GCV) has filed a definitive proxy statement for its Annual Meeting of Stockholders on May 11, 2026, primarily to elect four directors: three (Vincent D. Enright, Anthonie C. van Ekris, Salvatore J. Zizza) by holders of common and 5.20% Series H Preferred Stock voting together, and one (Anthony S. Colavita) by Preferred Stock holders separately. As of the March 12, 2026 record date, 20,050,323 common shares and 607,500 Preferred shares were outstanding, with no dividend arrearages reported. Major holders include GAMCO Investors, Inc. affiliates (9.6% of common) and Regina Pitaro (46.9% of Preferred).

• ·Board consists of 13 directors, 10 of whom are independent (non-interested persons under 1940 Act).
• ·Preferred stockholders elect two directors separately; currently Anthony S. Colavita and Werner J. Roeder.
• ·No dividend arrearages on Preferred Stock.
• ·Fiscal year ended September 30, 2025; annual report available upon request.
• ·Quorum requires majority of votes entitled to be cast; Preferred election requires majority of outstanding Preferred shares.

19-03-2026

Alamo Group Inc. (ALG) filed a DEFA14A definitive additional proxy statement on March 19, 2026, pursuant to Section 14(a) of the Securities Exchange Act of 1934. The filing indicates no fee was required and contains primarily boilerplate administrative details with no specific proposals, financial metrics, or shareholder matters disclosed in the provided content.

19-03-2026

Signet Jewelers reported full year Fiscal 2026 sales of $6.81B, up 1.6% YoY with SSS growth of 1.3% and adjusted operating income of $515.0M, up from $498.1M in FY25, driven by AUR increases of 7% and gross margin expansion. However, Q4 sales were nearly flat at $2.35B with SSS declining 0.7% YoY, adjusted operating income fell to $327.3M from $355.5M, and gross margin rate declined 60 bps due to merchandise margin pressure and fixed cost deleverage. Fiscal 2027 guidance projects sales of $6.6-6.9B with SSS ranging from -1.25% to +2.5%, alongside a quarterly dividend increase to $0.35 per share.

• ·Cash flow from operations FY26: $678.8M, up from $590.9M in FY25
• ·Capital expenditures FY26: $153.5M
• ·Total liquidity ~$2.0B as of Jan 31, 2026
• ·Q1 FY27 guidance: sales $1.53-1.57B, SSS 0.5-2.5%, adjusted operating income $66-77M
• ·FY27 guidance: adjusted operating income $470-560M, adjusted EBITDA $655-745M, adjusted diluted EPS $8.80-10.74
• ·FY27 capex planned $150-180M, net sq ft decrease low single digits
• ·Non-cash impairments FY26: $91.3M (largely digital brands), Q4 $6.6M (Diamonds Direct)
• ·Share repurchase authorization remaining: $518M
• ·Recognized as one of 2026 World’s Most Ethical Companies by Ethisphere

19-03-2026

Mount Logan Capital Inc. (MLCI) announced that its managed Opportunistic Credit Interval Fund (SOFIX) entered a definitive agreement to acquire over $100 million in assets from Yieldstreet Alternative Income Fund (YS AIF), nearly doubling SOFIX's size and expected to boost MLCI's annual fee-related earnings (FRE) by at least $2.8 million, or more than 30% of trailing twelve-month FRE as of December 31, 2025. The transaction, including a Transition Services Agreement (TSA) with Willow Wealth, is projected to be immediately accretive to FRE upon closing in late Q2 or Q3 2026, subject to regulatory and YS AIF shareholder approvals. MLCI had over $2.1 billion in assets under management as of December 31, 2025.

• ·YS AIF suspended share offerings effective immediately, but automatic dividend reinvestment plan continues.
• ·Transaction unanimously approved by SOFIX Board of Trustees and YS AIF Board of Directors.
• ·Intended as tax-free reorganization for YS AIF shareholders; no SOFIX shareholder vote required.
• ·TSA stock subject to lock-up provisions.

19-03-2026

SELLAS Life Sciences reported FY2025 financial results with R&D expenses decreasing 16% YoY to $16.0M and G&A expenses nearly flat at $12.3M (down 1% YoY), resulting in a narrowed net loss of $26.9M ($0.25/share) versus $30.9M ($0.50/share) in FY2024, bolstered by cash of $71.8M at year-end and additional $42.6M from warrant exercises in Q1 2026. Clinical programs advanced with 72 events reached in the Phase 3 REGAL trial for GPS (nearing the 80-event threshold for final analysis) and positive Phase 2 SLS009 data in r/r AML showing 46% ORR. However, the company continues to incur net losses, and G&A expenses showed minimal decline.

• ·Phase 2 SLS009 r/r AML: mOS 8.9 months in least pretreated cohort (vs expected 2.6 months); no DLTs or treatment-related deaths.
• ·REGAL trial: event-driven with 80 events required for final analysis; 72 events as of Dec 26, 2025.
• ·Preclinical SLS009: significant survival benefit in T-PLL model vs VEN alone (ESMO 2025); AACR 2026 poster on apoptosis in AML cell lines April 21, 2026.
• ·Warrant proceeds 2025: $54.6M from specific warrants ($23.6M Jan 2025 + $31.0M 2024 issues) + $12.6M others.

19-03-2026

Aclarion, Inc. announced that its Board unanimously adopted a limited duration stockholder rights plan, effective immediately and expiring in one year on March 18, 2027, to protect shareholder value by deterring unapproved acquisitions of 10% or more of common stock without a control premium. Rights will distribute as a dividend on March 30, 2026, for each share of common stock and Rights-Eligible Warrants, becoming exercisable upon triggering events to allow holders (excluding the acquirer) to purchase preferred stock equivalent to twice the $14.00 exercise price in common stock value. The plan applies equally to all stockholders, grandfathering existing >10% owners from triggering if they do not increase holdings, and was not adopted in response to any specific takeover threat.

• ·Rights attach to each share of Common Stock (par value $0.00001) and Rights-Eligible Warrants as of Record Date March 30, 2026
• ·Board may redeem rights at $0.001 per right or exchange for one share of Common Stock per right
• ·No dead-hand, slow-hand, or similar features limiting future Board actions
• ·Aclarion leverages MRS, biomarkers, and AI for chronic low back pain via Nociscan SaaS platform

19-03-2026

Eledon Pharmaceuticals reported FY2025 net loss of $45.6M, up from $36.2M in FY2024, driven by a 27.5% increase in R&D expenses to $66.3M due to clinical advancements, though G&A expenses declined 8.7% to $17.0M. Positive clinical updates include 24-month Phase 1b data showing improved eGFR (67.0 to 74.2 mL/min/1.73 m²) with no rejections in kidney transplant patients and 100% insulin independence in 10 type 1 diabetes patients on tegoprubart post-islet transplant; tegoprubart also received FDA Orphan Drug designation for liver transplantation. Cash and equivalents rose to $22.8M, with total current assets at $135.7M despite a decline from $143.7M prior year.

• ·No episodes of biopsy-proven acute rejection, graft loss, death, new-onset diabetes mellitus, or de novo donor-specific antibody formation in Phase 1b kidney transplant study.
• ·Mean most recent HbA1c of approximately 5.35% in 10 insulin-independent type 1 diabetes patients.
• ·Warrant liabilities decreased to $11.4M from $44.9M.
• ·Adjusted net loss excluding warrant changes: $79.1M in FY2025 vs $67.1M in FY2024.
• ·Basic EPS: $(0.52) FY2025 vs $(0.66) FY2024.

19-03-2026

Artificial Intelligence Technology Solutions, Inc. (AITX) filed an 8-K on March 19, 2026, under Items 8.01 and 9.01, announcing the issuance of a press release titled 'AITX's RAD Books Hundreds of SARA Licenses as Customers Expand After Initial Deployment.' The press release is furnished as Exhibit 99.1 and is not deemed filed or material.

• ·Filed by newsfilecorp.com
• ·Registrant details: Nevada incorporation, Commission File Number 000-55079, IRS Employer Identification No. 27-2343603, principal offices at 10800 Galaxie Avenue, Ferndale, Michigan 48220

19-03-2026

Modiv Industrial, Inc. announced it will report financial results for the quarter and full year ended December 31, 2025, after market close on March 25, 2026. The company declared a quarterly dividend of $0.4609375 per share on its 7.375% Series A Cumulative Redeemable Perpetual Preferred Stock, payable April 15, 2026, and monthly distributions of $0.10 per share on Class C Common Stock for April, May, and June 2026, equivalent to an annualized $1.20 per share. No comparative financial metrics were provided in the filing.

• ·Board authorized dividends and distributions on March 17, 2026.
• ·Series A Preferred record date: March 31, 2026.
• ·Common Stock record dates: April 30, May 29, June 30, 2026.
• ·Common Stock payment dates: May 15, June 15, July 15, 2026.

19-03-2026

Selectis Health, Inc. appointed Richard Huebner, age 68, as a new member of its Board of Directors effective March 12, 2026. Mr. Huebner, senior managing partner at GVC Capital LLC since 2001, has extensive experience in investment banking, compliance, and legal roles at firms including Fiserv Correspondent Services and Hanifen Imhoff Inc. He will receive an annual stipend of $30,000 under the company's Outside Directors Compensation Plan.

• ·Richard Huebner served as registered investment advisor (2000-2001), Executive Vice President at Fiserv Correspondent Services (1984-2000), and various roles at Hanifen Imhoff entities (1979-1997) and First Mid America, Inc. (1980-1983).
• ·Education: Bachelor’s degree from Hastings College (1979); Juris Doctorate from University of Nebraska (1982).

19-03-2026

Pelthos Therapeutics reported Q4 2025 ZELSUVMI net product revenue of $9.1M, up 28% QoQ from $7.1M in Q3, with total 2025 net product revenue reaching $16.2M since July launch and 129% QoQ unit growth to 6,232 units. However, Q4 operating loss improved to $12.0M from $15.4M in Q3, but net loss widened to $21.7M due to a $15.0M change in fair value of convertible debt, amid high SG&A of $18.5M and full-year net loss of $43.3M. The company completed acquisitions of XEPI in Nov 2025 and XEGLYZE in Jan 2026, raised $18M in convertible notes and $30M from a $50M term loan, bolstering cash to $18M as of Dec 31, 2025.

• ·Cash grew to $18.0M as of Dec 31, 2025 from $0.5M in 2024; total assets $130.4M vs $1.4M.
• ·Q4 COGS $1.7M vs $2.3M Q3; adjusted COGS $0.1M Q4 vs $0.4M Q3.
• ·Impetigo affects ~3M people/year in U.S.; head lice ~6-12M infestations/year.

19-03-2026

Kolibri Global Energy Inc. (KGEI), a foreign private issuer and emerging growth company, filed its Form 40-F Annual Report for the fiscal year ended December 31, 2025, incorporating by reference its Annual Information Form (AIF), Management’s Discussion and Analysis (MD&A), and audited consolidated financial statements for 2025 and 2024 prepared under IFRS. The company reported 35,471,833 common shares outstanding as of December 31, 2025, with shares listed on Nasdaq Capital Market (KGEI) and Toronto Stock Exchange. Management certified effective disclosure controls and internal controls over financial reporting, with no material changes or errors noted.

• ·Audit committee financial expert: Doug Urch (independent).
• ·Principal executive offices: 925 Broadbeck Drive, Suite 220, Thousand Oaks, CA 91320.
• ·Shareholder special meeting on November 25, 2025, limited authorized common shares to 37,367,894 without approval.
• ·No off-balance sheet arrangements material to investors.
• ·No waivers to Code of Business Conduct and Ethics in 2025.

19-03-2026

Chicago Atlantic BDC, Inc. (LIEN) reported Q4 2025 total investment income of $14.2M (up 12.5% YoY) and net investment income of $8.3M ($0.36/share), with full-year NII of $33.1M ($1.45/share, up 250% YoY); NAV per share rose slightly to $13.30 (up 0.8% YoY and 0.2% QoQ). The portfolio stood at $333.3M across 39 companies with no non-accruals and a 15.8% weighted average yield, while funding $31.7M in Q4 and $93.9M subsequently; however, liquidity declined to $47.5M as of March 18, 2026 from $77.9M at year-end, and Q4 saw minor unrealized depreciation of $20.6k. The Board declared a steady $0.34/share dividend (sixth consecutive quarter), payable April 14, 2026.

• ·Principal amortization and repayments of $11.0M in Q4 2025.
• ·Subsequent to year-end: two positions paid off totaling $13.6M; $54.5M outstanding on senior credit facility as of March 18, 2026.
• ·Pipeline exceeding $732M as of Dec 31, 2025.

19-03-2026

Almonty Industries Inc. filed its Form 40-F annual report for the fiscal year ended December 31, 2025, incorporating the Annual Information Form, audited consolidated financial statements, and Management's Discussion and Analysis as exhibits. The company reported 262,776,228 common shares outstanding as of December 31, 2025. Auditor fees increased substantially YoY to CAD $775,084 in 2025 from CAD $369,500 in 2024, driven by higher audit fees, with no other non-audit fees reported.

• ·Company qualifies as an emerging growth company.
• ·No off-balance sheet arrangements.
• ·No notices pursuant to Regulation BTR sent during 2025.
• ·Common shares listed on TSX, ASX, and Nasdaq.
• ·Audited by Zeifmans LLP (Firm ID: 1149), Toronto, Canada.

19-03-2026

Prologis, Inc. filed definitive additional proxy materials (DEFA14A) on March 19, 2026, for its 2026 Annual Meeting scheduled virtually on April 28, 2026, at 1:30 P.M. Pacific Time. Shareholders are asked to vote on the election of 11 director nominees, an advisory approval of 2025 executive compensation, and ratification of KPMG LLP as the independent auditor for 2026, with the board recommending FOR all items. Voting must be completed by April 27, 2026, 11:59 P.M. ET.

• ·Proxy materials available online at www.ProxyVote.com; paper/email copies requestable by April 14, 2026.
• ·Virtual meeting access at www.virtualshareholdermeeting.com/PLD2026.

19-03-2026

Satellogic reported Q4 2025 revenue of $6.2 million, up 94% YoY from $3.2 million, driven by Data & Analytics growth to $5.8 million (+152% YoY), though Space Systems revenue declined to $0.4 million from $0.9 million. Full-year 2025 revenue rose 38% YoY to $17.7 million, with improved Adjusted EBITDA loss of $17.4 million (48% better YoY) and cash position of $94.4 million, bolstered by $90 million and $35 million offerings; however, the company still posted a FY net loss of $4.8 million and flat/declining Space Systems revenue at $1.7 million.

• ·RPO breakdown: $6.7M in years 1-2, $8.0M in years 2-3, $21.8M thereafter.
• ·Merlin first launch targeted for October 2026, full operational capability H1 2027.
• ·Albania contract extension: 11 months.

19-03-2026

Vericel Corporation filed definitive additional proxy soliciting materials for its 2026 Annual Meeting of Shareholders, to be held virtually on April 29, 2026 at 9:00 a.m. ET. Shareholders are asked to vote on the election of seven director nominees, an advisory approval of named executive officer compensation, and ratification of PricewaterhouseCoopers LLP as the independent auditor for the fiscal year ending December 31, 2026, with the Board recommending 'For' all proposals. Voting must be completed by April 28, 2026, and proxy materials including the Notice, Proxy Statement, and Form 10-K are available online at www.ProxyVote.com.

• ·Annual Meeting is virtual only at www.virtualshareholdermeeting.com/VCEL2026; no in-person attendance.
• ·Request paper/email copies of materials by April 15, 2026 via www.ProxyVote.com, 1-800-579-1639, or sendmaterial@proxyvote.com.
• ·Company address: 64 Sidney Street, Cambridge, MA 02139.

19-03-2026

Lincoln Electric Holdings Inc's 2026 Proxy Statement details the virtual annual meeting on April 17, 2026 (record date February 27, 2026), with proposals to elect 10 director nominees, ratify Ernst & Young LLP as independent auditors for the year ending December 31, 2026, and approve NEO compensation on an advisory basis. The company reported $4.2B in 2025 sales from 71 manufacturing facilities across 20 countries serving 160+ countries, and outlined its RISE Strategy with 2030 targets including high single-digit to low double-digit sales CAGR, 19% average adjusted operating income margin, and mid-teens adjusted EPS CAGR. No declines or flat performance metrics were disclosed.

• ·Annual meeting voting deadline: April 16, 2026 (phone, internet, mail, or during virtual meeting)
• ·Fiscal year end: December 31
• ·2030 non-financial metrics: Safety, Growth, Productivity, Teamwork, Talent (equally weighted)

19-03-2026

GENELUX Corp (GNLX) filed its 10-K on March 19, 2026, disclosing it has incurred significant losses since inception, generated no revenue from product sales, and anticipates continued increasing losses without achieving profitability. The company relies on its sole clinical-stage product candidate, Olvi-Vec, in Phase 3 trials for PRROC, but highlights substantial risks including need for additional financing, regulatory delays, manufacturing challenges, and high dependence on this single asset with no approved products. Forward-looking plans involve advancing trials, manufacturing expansion, and hiring, but emphasize uncertainties in commercialization and market acceptance.

• ·Never generated any revenue from commercially approved product sales
• ·Only one product candidate (Olvi-Vec) in clinical development
• ·Highly dependent on key personnel including President, Chief Executive Officer and Chairman

19-03-2026

Accel Entertainment, Inc. (ACEL) filed a DEFA14A Definitive Additional Proxy Materials on March 19, 2026, pursuant to Section 14(a) of the Securities Exchange Act of 1934. The filing indicates no fee was required and is marked as Definitive Additional Materials for proxy solicitation. No substantive financial data, proposals, or shareholder matters are detailed in the provided header content.

19-03-2026

First Commonwealth Financial Corporation issued a notice of availability of proxy materials for its 2026 Annual Shareholders’ Meeting on April 28, 2026, at 1:00 P.M. ET, held virtually. Key proposals include the election of 12 director nominees, ratification of Ernst & Young LLP as independent auditors for 2026, and an advisory vote on named officer compensation, with the Board recommending a vote FOR all items. Shareholders must access materials online at www.envisionreports.com/FCF or request paper copies by April 16, 2026.

• ·Virtual attendance via https://meetnow.global/MQPU7JP using 15-digit control number.
• ·Paper copy requests via www.envisionreports.com/FCF, 1-866-641-4276, or investorvote@computershare.com must be received by April 16, 2026.
• ·Includes 2025 Annual Meeting Minutes, 2025 Annual Report, and 2026 Proxy Statement available online.

19-03-2026

Revelation Biosciences, Inc. held a Special Meeting of Stockholders on March 18, 2026, where shareholders overwhelmingly approved Proposal 1 to authorize the issuance of common stock pursuant to Class J Common Stock Warrants (issued January 26, 2026) to exceed Nasdaq's 20% Exchange Cap, with 4,033,345 votes for, 104,162 against, and 34,228 abstentions out of 4,171,735 shares present (quorum met from 10,492,469 outstanding shares). Proposal 2 for discretionary adjournment also passed strongly (4,044,322 for, 92,422 against). Following approval, the warrants' expiration date extends to March 18, 2031.

• ·Definitive proxy statement filed with SEC on February 17, 2026
• ·Warrant inducement letter dated January 23, 2026
• ·No broker non-votes on either proposal
• ·Common stock par value $0.001 per share

19-03-2026

York Space Systems reported full-year 2025 revenue of $386.2M, up 52% YoY from $253.5M, driven by Transport Layer Tranche 2 contracts, with gross profit surging 133% to $75.5M and gross margin expanding 6.8pp to 19.5%. However, net loss narrowed to $84.5M from $98.9M (-15%), while Adjusted EBITDA improved to -$8.3M from -$43.0M (-81%) but remained negative. Backlog grew to $543M after converting $319M to revenue, supported by acquisitions of ATLAS Space Operations and Orbion Space Technology, and 2026 revenue guidance of $545-595M.

• ·Liquidity of $312.6M as of Dec 31, 2025, increasing to $895.4M post-IPO as of Jan 31, 2026.
• ·IPO: 18.5M shares at $34 per share on Jan 30, 2026.
• ·Acquired ATLAS Space Operations in 2025; acquired Orbion Space Technology in March 2026.
• ·Dragoon mission delivered in 7 months from contract (75% timeline reduction vs. typical 30 months).
• ·2026 revenue outlook: $545M to $595M, with >70% from existing backlog at midpoint.

19-03-2026

Intellicheck, Inc. reported FY2025 revenues of $22.7M, up 13% YoY from $20.0M, with gross profit rising 13% to $20.5M and net income of $1.3M versus a $0.9M loss in 2024; Adjusted EBITDA surged to $2.6M from $0.5M. However, gross margin slipped slightly to 90.4% from 90.8%, R&D expenses increased 38% to $5.3M, and total operating expenses were essentially flat at $19.4M.

• ·Cash flows from operating activities: $4.5M in FY2025 vs $(2.7M) used in FY2024.
• ·Allowance for credit losses: $157k (2025) vs $100k (2024).
• ·Intangible assets, net: $2.1M (2025) down from $2.4M (2024).
• ·Weighted average basic shares: 19,546,473 (2025) vs 19,327,132 (2024).

19-03-2026

Church & Dwight Co., Inc.'s 2026 Proxy Statement details the virtual annual stockholder meeting on May 1, 2026 at 12:00 p.m. EDT (record date March 4, 2026), seeking election of 11 director nominees (10 independent), advisory approval of named executive officer compensation, ratification of Deloitte & Touche LLP as 2026 auditors, and rejection of a stockholder proposal for written consent action. The Board, led by independent Chairman Ravichandra K. Saligram, highlights strong governance including majority voting, age 75 retirement policy, overboarding limits (4 public boards for non-employees, 2 for CEO), and 100% compliance with attendance (at least 75% of 2025 meetings). No performance declines or flat metrics are noted in the governance disclosures.

• ·Annual meeting virtual location: www.virtualshareholdermeeting.com/CHD2026
• ·Director retirement age limit: 75
• ·Overboarding limits: 4 public company boards for non-employee directors; 2 for CEO
• ·All directors in compliance with overboarding policy
• ·Filing date: March 19, 2026

19-03-2026

Constellation Acquisition Corp I amended its promissory note with sponsor Constellation Sponsor LP on March 18, 2026, increasing the total principal amount from $2.25M to $5.25M via a $3M addition. The amendment also restates drawdown provisions, allowing up to $5.195M in additional aggregate funding until a business combination is consummated. No other changes to the note terms were made.

• ·Original promissory note dated January 30, 2024.
• ·First amendment dated June 5, 2025.
• ·Drawdowns funded within 3 business days of request; no fees on drawdowns.

19-03-2026

Armour Residential REIT, Inc. filed Definitive Additional Materials (DEFA14A) on March 19, 2026, as part of its proxy statement pursuant to Section 14(a) of the Securities Exchange Act of 1934. The filing indicates no fee was required and is marked as definitive additional materials for the 2025 proxy. No financial metrics, performance data, or other substantive details are provided in the filing header.

19-03-2026

Corvex, Inc. announced the closing of an all-stock merger with Movano Inc. on March 19, 2026, pursuant to which Movano will be renamed Corvex, Inc. effective March 23, 2026, and continue trading on Nasdaq under 'MOVE'. Prior to the merger, Corvex and Movano raised $40.2 million to expand its AI infrastructure platform. The merger includes issuance of preferred stock convertible into common stock (Series B up to 19.9% ownership), a stock dividend of 0.358 shares per common share (record date March 30, 2026), and upcoming stockholder meeting by May 31, 2026, for approvals including conversions and leadership changes.

• ·Issued 240.562 shares of Series B Convertible Preferred Stock (auto-converts to 240,562,000 common shares on March 31, 2026).
• ·Issued 23,551.5195 shares of Series C Non-Voting Convertible Preferred Stock (conversion subject to stockholder approval; each converts to 1,000 common shares).
• ·Issued 30,227.0524 shares of Series D Non-Voting Convertible Preferred Stock (conversion subject to approval; each converts to 1,000 common shares; 4.99% ownership limit).
• ·2026 Stockholders’ Meeting no later than May 31, 2026, to vote on conversions, option exercises, director elections, auditor ratification, and equity incentive plans.
• ·Merger qualifies as tax-free reorganization under IRC Section 368(a).

19-03-2026

Marvell Technology, Inc. filed an 8-K on March 19, 2026, under Item 8.01 to disclose a prospectus supplement to its automatic shelf registration statement on Form S-3 (Registration No. 333-285742). The filing attaches the legal opinion of Wilson Sonsini Goodrich & Rosati, Professional Corporation confirming the legality of securities issuance and sale as described in the prospectus supplement. No financial metrics or performance data were reported.

• ·Commission File Number: 001-40357
• ·IRS Employer Identification No.: 85-3971597
• ·Exhibits filed: 5.1 (Opinion), 23.1 (Consent), 104 (Cover Page Interactive Data File)

19-03-2026

electroCore reported record full-year 2025 net sales of $32.0 million, up 27% YoY from $25.2 million, driven by 25% growth in U.S. prescription business and 97% surge in general wellness sales, however TAC-STIM declined 65% and outside U.S. grew only 6%. GAAP net loss widened to $14.0 million from $11.9 million amid higher operating expenses, with total cash slightly down to $11.6 million from $12.2 million and stockholders' equity turning to a $(1.7) million deficit. The company guides ~30% revenue growth for 2026 alongside CEO Dan Goldberger's retirement and key leadership changes.

• ·R&D expenses increased $0.4M to $2.7M due to gammaCore Emerald development.
• ·SG&A expenses rose $7.0M to $38.2M, driven by $3.8M variable sales expenses and $0.5M bad debt.
• ·Stockholders’ equity shifted to $(1.7)M deficit from $7.5M positive.

19-03-2026

Kohl's Corporation reported FY2025 net sales of $14.8B, down 4.0% YoY from $15.4B, with declines across most categories including Women's (-5.7%), Men's (-4.8%), Home (-4.3%), Children's (-6.5%), and Footwear (-6.9%), though Accessories (including Sephora) grew 2.0%. GAAP operating income improved to $624M from $433M, net income to $272M ($2.38 diluted EPS) from $109M ($0.98), aided by lower impairments/store closing costs ($15M vs $76M) and a $129M legal settlement gain; adjusted metrics showed flat operating income ($510M vs $509M) and slight net income growth ($186M vs $167M). Cash from operating activities surged to $1.4B from $648M, driving adjusted free cash flow to $935M from $104M.

• ·Cash and cash equivalents ended FY2025 at $674M, up from $134M in FY2024.
• ·Depreciation and amortization decreased to $700M in FY2025 from $743M in FY2024.
• ·Interest expense, net fell to $288M in FY2025 from $319M in FY2024.
• ·Provision for income taxes was $64M in FY2025 (19.0% effective rate) vs $5M (3.9%) in FY2024.

19-03-2026

SentinelOne reported FY2026 revenue of $1.00B, up 22% YoY from $821M, with ARR reaching $1.12B (up 22% YoY from $920M) and achieving Non-GAAP operating income of $35M versus a $25M loss prior year. However, GAAP operating loss improved modestly to $321M from $329M, while net loss widened to $451M from $288M due to a $171M tax provision; operating expenses remained high at 106% of revenue, with sales and marketing at 52%. Gross margin held steady at 74%.

• ·R&D expenses increased 21% YoY to $324M in FY2026.
• ·Restructuring charges of $12.3M in FY2026 operating expenses.
• ·Stock-based compensation as % of revenue declined to ~30% in FY2026 from higher prior levels.

19-03-2026

Universal Logistics Holdings, Inc. dismissed Grant Thornton LLP as its independent registered public accounting firm on March 13, 2026, effective upon the filing of its Form 10-K on March 16, 2026. Audit reports for fiscal years ended December 31, 2025 and December 31, 2024 were unqualified with no disagreements on accounting matters; however, a previously disclosed material weakness in internal controls over financial reporting persists, involving deficiencies in controls, insufficient technical accounting expertise, and ineffective review of complex transactions.

• ·No disagreements with Grant Thornton on accounting principles, financial disclosures, or auditing scope during fiscal years ended December 31, 2025 and 2024, or interim period through March 16, 2026.
• ·Grant Thornton authorized to respond fully to successor auditor inquiries on the material weakness.
• ·Grant Thornton letter (Exhibit 16.1) confirms agreement with disclosures.

19-03-2026

The Gabelli Equity Trust Inc. has filed a definitive proxy statement for its annual stockholder meeting on May 11, 2026, at 9:00 a.m. ET in Greenwich, CT, primarily to elect four directors: three (Laura Linehan, Anthonie C. van Ekris, Salvatore J. Zizza) by common and preferred stockholders voting together as a single class, and one (Frank J. Fahrenkopf, Jr.) by preferred stockholders as a separate class. The record date is March 12, 2026, with 311,196,702 common shares and approximately 14.1M total preferred shares outstanding across Series G, H, K, M, and Q. No financial performance metrics or period-over-period comparisons are provided in the filing.

• ·Board consists of 12 Directors, 9 independent (not interested persons under 1940 Act).
• ·Nominees to serve three-year terms until 2029 Annual Meeting.
• ·Current Directors serving until 2028: Mario J. Gabelli, Leslie F. Foley, William F. Heitmann, Eileen Cheigh Nakamura.
• ·Current Directors serving until 2027: Elizabeth C. Bogan, James P. Conn, Michael J. Ferrantino, Agnes Mullady.
• ·Proxy materials mailing begins on or about April 1, 2026.

19-03-2026

Ellsworth Growth and Income Fund Ltd. has issued a definitive proxy statement for its Annual Meeting of Shareholders on May 11, 2026, at 8:15 a.m. ET in Greenwich, CT, primarily to elect four Trustees: Kinchen C. Bizzell, James P. Conn, and Frank J. Fahrenkopf, Jr. by common and preferred shareholders voting together as a single class, and Michael J. Melarkey by preferred shareholders as a separate class. The record date is March 12, 2026, with 13,670,303 Common Shares, 1,103,002 Series A Preferred Shares, and 273,000 Series B Preferred Shares outstanding. Major beneficial owners include Saba Capital Management (11.7% of Common Shares) and GAMCO Investors (10.5% of Preferred Shares).

• ·Quorum requires holders of one-third of outstanding shares entitled to vote.
• ·No dividend arrearages on Preferred Shares as of filing date.
• ·Fund's fiscal year ended September 30, 2025; annual report available upon request.
• ·Board has 11 Trustees, 9 independent (non-interested persons).
• ·Preferred shareholders entitled to elect minimum number of Trustees representing a majority if dividends in arrears for two full years.

19-03-2026

The Gabelli Global Small & Mid Cap Value Trust (GGZ) has filed a definitive proxy statement (DEF 14A) for its Annual Meeting of Shareholders on May 11, 2026, at 8:45 a.m. ET, to elect three Trustees—Mario J. Gabelli, James P. Conn, and Salvatore J. Zizza—for terms expiring at the 2029 Annual Meeting. As of the record date March 12, 2026, 7,640,349 Common Shares and 4,000,000 5.20% Series E Cumulative Preferred Shares were outstanding, with GAMCO Investors, Inc. and affiliates holding 36.8% of Common Shares and 49.5% of Preferred Shares. No dividend arrearages on Preferred Shares were reported, and the Board consists of nine Trustees, with Common and Preferred shareholders voting together as a single class for these nominees.

• ·Quorum requires holders of one-third of outstanding shares entitled to vote.
• ·Preferred shareholders elect two Trustees separately (currently Frank J. Fahrenkopf, Jr. and John Birch).
• ·No dividend arrearages on Preferred Shares as of proxy statement date.
• ·Proxy solicitation costs borne by the Fund, with reimbursement to brokers.

19-03-2026

The Gabelli Multimedia Trust Inc. (GGT-PG) has filed a definitive proxy statement for its Annual Meeting of Stockholders on May 11, 2026, at 9:15 a.m. ET, to elect four directors—Frank J. Fahrenkopf, Jr., Werner J. Roeder, Salvatore J. Zizza, and Daniel E. Zucchi—for three-year terms ending at the 2029 annual meeting. Common and Preferred stockholders (Series E and G, both 5.125% Cumulative) vote together as a single class; as of the March 12, 2026 record date, 41,809,633 Common shares, 1,566,270 Series E Preferred shares, and 1,202,217 Series G Preferred shares were outstanding. No dividend arrearages exist on Preferred Stock.

• ·Annual meeting location: Indian Harbor Yacht Club, 710 Steamboat Road, Greenwich, Connecticut, 06830
• ·Notice of Internet Availability of Proxy Materials mailed on or about April 1, 2026
• ·Fund's fiscal year ended December 31, 2025; annual report available upon request
• ·Board divided into three classes with staggered three-year terms
• ·No Preferred Stock dividend arrearages as of proxy statement date

19-03-2026

On March 17, 2026, Kimball Electronics, Inc. published its 2025 Guiding Principles Report, serving as the company's annual sustainability report, on its website at www.kimballelectronics.com/sustainability. A press release announcing the publication is attached as Exhibit 99.1. The information is furnished and not deemed filed under Section 18 of the Securities Exchange Act of 1934.

• ·Filing date: March 19, 2026
• ·Event date: March 17, 2026
• ·Website: www.kimballelectronics.com/sustainability